Time saved in disease progression for treatments in AD (including 3 monoclonal antibodies and 2 other promising treatments)

Aduhelm (aducanumab) - Eisai, Biogen

ondansetron ultra-low dose (AD04) - Adial

Leqembi (lecanemab-irmb) - Biogen, BioArctic, Eisai

alhydrogel injectable (AD04) - ADvantage Therap

donanemab (LY3002813) - Eli Lilly

https://alz.confex.com/alz/2023/meetingapp.cgi/Paper/83240

Samuel P. Dickson , Ph.D; Benjamin A Haaland , PhD; Suzanne B. Hendrix , Ph.D; Craig Mallinckrodt , PhD; Patrick P O'Keefe , PhD; Mitchell Wassom , MS

Jul 7, 2023